摘要
目的 探究培元通脑胶囊对患者神经功能的改善价值。方法 回顾性队列分析缺血性脑卒中患者的病历资料。对照组口服阿司匹林肠溶片,每次100 mg(qd),静脉滴注低分子右旋糖酐500 mL(qd),口服阿托伐他汀钙20 mg(qd),均治疗12周;试验组在对照组的基础上给予培元通脑胶囊1.8 g(tid),治疗12周。对比2组治疗12周后临床疗效、神经功能[美国国立卫生院神经功能缺损(NIHSS)评分]、中医证候积分、实验室指标[降钙素基因相关肽(CGRP)、血浆D-二聚体(D-D)、中性粒细胞与淋巴细胞比例(NLR)]、血流动力学[全血黏度、血小板聚集率、纤维蛋白原(FIB)、红细胞沉降率(ESR)]以及治疗期间药物不良反应发生情况。结果 治疗12周后,试验组和对照组的总有效率分别为77.50%(31例/40例)和55.00%(22例/40例),差异有统计学意义(P<0.05)。治疗12周后,试验组和对照组的NIHSS评分分别为(6.09±1.03)和(10.23±2.03)分,中医证候积分分别为(12.57±2.82)和(15.78±3.12)分,CGRP水平分别为(35.47±6.24)和(30.12±6.11) pg·mL^(-1),D-D水平分别为(0.31±0.09)和(0.56±0.11) mg·mL^(-1),NLR水平分别为4.76±1.23和3.06±0.91,全血黏度分别为(3.11±0.62)和(3.74±0.84)mPa·s^(-1),血小板聚集率分别为(48.21±5.11)%和(54.69±6.31)%,FIB水平分别为(2.41±0.32)和(3.11±0.49)g·L^(-1),ESR分别为(18.11±2.06)和(23.45±2.15)mm·h^(-1),试验组上述指标与对照组比较,在统计学上差异均有统计学意义(均P<0.05)。试验组共6例发生药物不良反应,药物不良反应发生率为15.00%,对照组发生8例药物不良反应,药物不良反应发生率为20.00%,在统计学上差异无统计学意义(P>0.05)。结论 常规治疗方案联合培元通脑胶囊治疗比常规治疗缺血性脑卒中的疗效更佳,可改善神经功能和血流动力学,提高临床疗效。
Objective To explore the improvement value of Peiyuan Tongnao capsule on nerve function in patients.Methods Retrospective cohort analysis of patients with ischemic stroke was performed.Control group was treated for 12 weeks by oral aspirin enteric-coated tablets(100 mg,qd each time),intravenous infusion of low molecular dextran500 mL(qd),oral atorvastatin calcium 20 mg(qd);the treatment group was treated with Peiyuan Tongnao capsule 1.8 g(tid) for 12 weeks on the basis of the control group.After 12 weeks of treatment,clinical efficacy,neurological function [National Institutes of Health Neurological impairment(NIHSS) score],traditional Chinese medicine(TCM) syndrome score,laboratory indexes [calcitonin gene-related peptide(CGRP),plasma D-dimer(D-D),neutrophil to lymphocyte ratio(NLR)],and hemorheological indexes [whole blood viscosity,platelets aggregation rate,fibrinogen(FIB),blood sedimentation rate(ESR)] were compared between the two groups,and incidence of adverse drug reactions during treatment.Results After 12 weeks of treatment,the total effective rate of treatment group and control group was 77.50%(31 cases/40cases) and 55.00%(22 cases/40 cases),respectively,and the difference was statistically significant(P <0.05).After 12 weeks of treatment,the NIHSS scores of treatment group and control group were(6.09±1.03) and(10.23±2.03) points;the TCM syndrome scores were(12.57±2.82) and(15.78±3.12) points;CGRP levels were(35.47±6.24) and(30.12±6.11) pg · mL^(-1);D-D levels were(0.31±0.09) and(0.56±0.11)mg·mL^(-1);NLR levels were 4.76±1.23 and 3.06±0.91;whole blood viscosity were(3.11±0.62) and(3.74±0.84) mPa·s^(-1);platelet aggregation rate were(48.21±5.11) % and(54.69±6.31) %;FIB level were(2.41±0.32) and(3.11±0.49) g · L^(-1);ESR were(18.11±2.06) and(23.45±2.15) mm · h^(-1),respectively.The above indexes in treatment group were significantly different from those in control group(all P <0.05).There were 6 cases of adverse drug reactions in the treatment group,and the incidence of adverse dr
作者
王梦迪
赵英波
孙悦
张迪
WANG Meng-di;ZHAO Ying-bo;SUN Yue;ZHANG Di(Graduate School,Heilongjiang University of Chinese Medicine,Harbin 150006,Heilongjiang Province,China;Four Departments of Acupuncture and Moxibustion,First Affiliated Hospital,Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2024年第4期487-491,共5页
The Chinese Journal of Clinical Pharmacology
关键词
培元通脑胶囊
缺血性脑卒中
临床疗效
神经功能
中医证候积分
Peiyuan Tongnao capsule
schemic stroke
clinical efficacy
nerve function
traditional Chinese medicine syndrome score
